Exceptional results in neuroendocrine-metastases-caused paraplegia treatedwith [Y-90-DOTA]-D-Phe(1)-Tyr(3)-octreotide (Y-90-DOTATOC), a radiolabelled somatostatin analogue

Authors
Waldherr, C Haldemann, A Maecke, HR Crazzolara, A Mueller-Brand, J
Citation
C. Waldherr et al., Exceptional results in neuroendocrine-metastases-caused paraplegia treatedwith [Y-90-DOTA]-D-Phe(1)-Tyr(3)-octreotide (Y-90-DOTATOC), a radiolabelled somatostatin analogue, CL ONCOL-UK, 12(2), 2000, pp. 121-123
Citations number
8
Categorie Soggetti
Oncology
Journal title
CLINICAL ONCOLOGY
ISSN journal
09366555 → ACNP
Volume
12
Issue
2
Year of publication
2000
Pages
121 - 123
Database
ISI
SICI code
0936-6555(2000)12:2<121:ERINPT>2.0.ZU;2-X
Abstract
The case history is presented of a patient with paraplegia caused by progre ssive spinal cord compression due to bone metastases of a neuroendocrine pu lmonary tumour. After failed external radiotherapy, the patient received ta rgeted internal radiotherapy administered as a fractionated treatment with intravenous injections of a total of 7400 MBq/m(2) of [Y-90-DOTA]-D-Phe(1)- Tyr(3)-octreotide (Y-90-DOTATOC), a radiolabelled somatostatin analogue. Th is case history highlights the value of Y-90-DOTATOC in the treatment of ne uroendocrine tumours and the importance and possibility of good palliation of neuroendocrine bone metastases.